^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

EGFR806-specific CAR T-cell therapy

i
Other names: EGFR806-specific chimeric antigen receptor (CAR) T cell therapy, second generation 4-1BBζ EGFR806-EGFRt, EGFR806-specific CAR T-cell therapy
Company:
Cellevolve Bio, Seattle Children's Hospital, Seattle Children’s Therapeutics
Drug class:
EGFR-targeted CAR-T immunotherapy
7ms
STRIvE-01: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov)
P1, N=44, Recruiting, Seattle Children's Hospital | Trial completion date: Jun 2038 --> Jun 2040 | Trial primary completion date: Jun 2024 --> Jun 2025
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression
|
EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19
over1year
STRIvE-01: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov)
P1, N=44, Recruiting, Seattle Children's Hospital | Trial primary completion date: Jun 2023 --> Jun 2024
Trial primary completion date • CAR T-Cell Therapy
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression
|
EGFR806-specific CAR T-cell therapy
over1year
Enrollment open • CAR T-Cell Therapy
|
EGFR806-specific CAR T-cell therapy • SC-CAR4BRAIN
almost2years
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors (clinicaltrials.gov)
P1, N=11, Active, not recruiting, Seattle Children's Hospital | Recruiting --> Active, not recruiting | N=36 --> 11
Enrollment closed • Enrollment change • CAR T-Cell Therapy • IO biomarker
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression • EGFR positive
|
EGFR806-specific CAR T-cell therapy
2years
EGFR as a potent CAR T target in triple negative breast cancer brain metastases. (PubMed, Breast Cancer Res Treat)
Our results demonstrates anti-tumor activity of EGFR806 CAR T cells against TNBC cells in vitro and in vivo. Given EGFR806 CAR T cells are currently undergoing clinical trials in primary brain tumor patients without obvious toxicity, our results are immediately actionable against the TNBC-BM patient population.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR806-specific CAR T-cell therapy • depatuxizumab (ABT-806)
over3years
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov)
P1, N=36, Recruiting, Seattle Children's Hospital | Trial completion date: Jun 2036 --> Jun 2038 | Trial primary completion date: Jun 2021 --> Jun 2023
Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
EGFR (Epidermal growth factor receptor) • CD19 (CD19 Molecule)
|
EGFR expression
|
EGFR806-specific CAR T-cell therapy